Mylan N.V., founded in 1961 and headquartered in Canonsburg, Pennsylvania, is a global pharmaceutical company dedicated to providing access to high-quality medicines. Mylan specializes in the development, manufacturing, and distribution of generic and specialty pharmaceuticals, with a significant portfolio that includes over 1,400 different products spanning various therapeutic areas.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| MYL 3.13% 2028-11-22 EURMylan N.V. | United Kingdom | 2028-11-22 | 3.125 | 2.93 |
| MYL 3.95% 2026-06-15 USDMylan N.V. | United Kingdom | 2026-06-15 | 3.950 | 4.57 |
| MYL 3.95% 2026-06-15 USDMylan N.V. | United Kingdom | 2026-06-15 | 3.950 | 4.45 |
| MYL 3.95% 2026-06-15 USDMylan N.V. | United Kingdom | 2026-06-15 | 3.950 | 4.57 |
| MYL 5.25% 2046-06-15 USDMylan N.V. | United Kingdom | 2046-06-15 | 5.250 | 6.68 |
| MYL 5.25% 2046-06-15 USDMylan N.V. | United Kingdom | 2046-06-15 | 5.250 | 6.68 |
| MYL 5.25% 2046-06-15 USDMylan N.V. | United Kingdom | 2046-06-15 | 5.250 | 6.68 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Mylan N.V. has a history of bond issuances that began in the early 2000s, with significant offerings occurring in 2016 to finance its merger with Pfizer's Upjohn business. These bonds featured various maturities and attractive yields relative to industry standards. Notably, Mylan's bonds gained attention for their strong demand during issuance, reflecting investor confidence despite the challenging regulatory environment in pharmaceuticals. As of recent assessments, current yields remain competitive, positioning Mylan favorably in the marketplace.